Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morphotek, a subsidiary of Eisai, has entered into a sponsored research agreement (SRA) with Hokkaido University to evaluate the anti-tumor effect of Amatuximab (MORAb-009) for advanced pancreatic cancer.
Subscribe to our email newsletter
Amatuximab (MORAb-009) is a monoclonal antibody that binds mesothelin, a cell surface protein on pancreatic, mesothelioma and a subset of other types of tumor cells.
Morphotek said that funding from this grant will support a pre-clinical study to evaluate the potential of Amatuximab alone and in combination with gemcitabine in an adjuvant setting.
Morphotek president and CEO Nicholas Nicolaides said that they were hopeful that the data may bring them one step closer to providing hope for these patients.